Shares of Alpine Immune Sciences, Inc. (ALPN Quick QuoteALPN - Free Report) have been climbing northward over the last three weeks. The single-biggest contributing factor has been the reportage that Povetacicept, the company’s flagship intravenous drug program, which is currently undergoing clinical development, has a high chance of approval.

Since the beginning of June, the Alpine Immune stock has surged 19%. ALPN’s shares closed out Wednesday at $11.85.

Alpine Immune Sciences, Inc. Price and Consensus

Alpine Immune Sciences, Inc. price-consensus-chart | Alpine Immune Sciences, Inc. Quote

This clinical-stage biopharmaceutical company, which focuses on the research and development of protein-based immunotherapies for the treatment of cancer and autoimmune/inflammatory disorders, has lately been in the pink on account of a flourishing healthcare sector.

Alpine Immune, which is part of the Zacks Medical – Drugs industry and currently has a Zacks Rank #3 (Hold), is riding on the positivity surrounding its pipeline. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

For the current year, the Zacks Consensus Estimate for earnings has moved up 5.3% over the past 60 days, while estimated sales growth is 18.2%. The Zacks Consensus Estimate for the full year is a loss of $1.43 per share, indicating a year-over-year increase of 17.3%. The consensus estimate for revenues is $35.5 million.

However, with a setback as recent as its cancer drug program failing late last year and a consensus loss estimate, one needs to take stock of the situation and see whether the company can sustain the current momentum.

Why Haven’t You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.

See Stocks Free >>